The post-marketing surveillance phase of drug development a. depends solely on the reports of prescribers of the drug. b. reports previously discovered toxic reactions. c. reports only short-term toxicity test results. d. includes surveys and reports of adverse reactions as well as consumer watchdog information.

D. includes surveys and reports of adverse reactions as well as consumer watchdog information.

Explanation:

The post-marketing surveillance phase of drug development includes adverse reaction research and reporting, as well as consumer surveillance information. These reports and surveys are conducted to confirm that the results obtained in previous phases are applicable to a large part of the population with the disease. This phase occurs after drug approval, when it is already marketed. These are post-marketing surveillance studies to establish therapeutic value, the emergence of new long-term adverse reactions or confirmation of known reactions and treatment strategies.

d.

hope to be marked brainliest

this protocol describes a detailed procedure for intracellular flow cytometry staining.